ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
Agendia’s MammaPrint and BluePrint Tests to Be Highlighted at San Antonio Breast Cancer Symposium
Expert Symposium Panel Will Offer Insights Into How Functional Molecular Subtypes Can Better Individualize Treatment IRVINE, CA and AMSTERDAM, THE NETHERLANDS – New breast cancer research on Agendia’s MammaPrint® and BluePrint® genomic tests will be presented Read More
Agendia Breast Cancer Test for Molecular Subtyping Improves Match of Therapy to Patient, Study Finds
IRVINE, CA and AMSTERDAM – New data from an ongoing study indicates the BluePrint genomic test provides information about the molecular subtype of breast cancer that adds value beyond what can be learned from conventional IHC-FISH pathology testing. Read More
Agendia Board of Directors Appoints Jan Egberts, M.D., as CEO
IRVINE, CA and AMSTERDAM – Agendia, Inc., a leading molecular diagnostic company, today announced the appointment of life science industry veteran and Agendia board member Jan H. Egberts, M.D., as CEO. He replaces David Macdonald, Read More
Agendia Test for Molecular Subtyping of Breast Cancer Is a Better Guide to Pre-Surgical Treatment, Study Finds
IRVINE, CA and AMSTERDAM – In findings that could eventually change the way breast cancer is treated, a study reports that the BluePrint genomic test provides more accurate information about the molecular subtype of breast Read More